B N Rathi Securities Regulatory Approval

Other Announcement

B N Rathi Securities Other Announcement

BN Rathi Securities Ltd has filed its quarterly shareholding pattern for the period ending September 30, 2026. This submission complies with SEBI Regulation 31 requirements.

Capital Structure Change

B N Rathi Securities Capital Structure Change

Darshan P Desai HUF and Priyanka Darshan Desai sold 5,45,163 and 4,75,991 shares of B.N. Rathi Securities, respectively, through open market transactions.

Annual General Meeting

B N Rathi Securities Annual General Meeting

B.N. Rathi Securities Ltd reported the conclusion of its 40th AGM. Shareholders approved financial statements, director appointments, and a dividend declaration.

Financial Results

B N Rathi Securities Q1 FY27 Results: Net Profit ₹2.5 Cr, Up 66.7% YoY

B N Rathi Securities Ltd reported revenue from operations of ₹16 Cr (+37.9% YoY) and net profit of ₹2.5 Cr (+66.7% YoY) for Q1 FY27.

Key figure

Net profit ₹2.5 Cr · +66.7% YoY

Board Meeting Date

B N Rathi Securities Board Meeting Date

B.N. Rathi Securities Ltd. will hold its 206th Board Meeting on August 12, 2026, to consider and approve the unaudited financial results for the quarter ended June 30, 2026.

Board Meeting Outcome

B N Rathi Securities Board Meeting Outcome

B.N. Rathi Securities Ltd approved a ₹0.60 Crore investment as a Sponsor Contribution to an Alternative Investment Fund managed by its associate, B-Fly Asset Manager LLP.

Value

₹0.60 Cr

Regulatory ApprovalShalby Ltd SHALBYAlfa AlertAn Alfa Alert is ALFA Finder's top-priority alert: filings that can move a stock, such as orders, fund raises and approvals, sent to subscribers on Telegram within seconds of reaching the exchange.

Shalby Regulatory Approval

Shalby Hospital, Jabalpur received CMHO permission to resume normal operations, including patient admissions, on its previously affected floor. The hospital has now fully resumed healthcare services.

Regulatory ApprovalElantas Beck India Ltd ELANTASAlfa AlertAn Alfa Alert is ALFA Finder's top-priority alert: filings that can move a stock, such as orders, fund raises and approvals, sent to subscribers on Telegram within seconds of reaching the exchange.

Elantas Beck India Regulatory Approval

Elantas Beck India's GPCB permanently revoked the closure direction on its Ankleshwar plant. The facility can keep operating, subject to compliance conditions.

Regulatory ApprovalKalyani Cast-Tech Ltd 544023Alfa AlertAn Alfa Alert is ALFA Finder's top-priority alert: filings that can move a stock, such as orders, fund raises and approvals, sent to subscribers on Telegram within seconds of reaching the exchange.

Kalyani Cast-Tech Regulatory Approval

Kalyani Cast-Tech received RDSO Stage-I concept design approval for its new container-carrying wagon under PWDA. Stage-II detailed design approval is still required, subject to dynamics simulation conditions.

Regulatory ApprovalMukka Proteins Ltd MUKKAAlfa AlertAn Alfa Alert is ALFA Finder's top-priority alert: filings that can move a stock, such as orders, fund raises and approvals, sent to subscribers on Telegram within seconds of reaching the exchange.

Mukka Proteins Regulatory Approval

Mukka Proteins received a US FDA facility registration certificate, valid October 1, 2026 to December 31, 2027. The company says the registration supports its engagement with US customers and markets.

Execution

October 1, 2026 to December 31, 2027

Regulatory ApprovalCanara Bank CANBKAlfa AlertAn Alfa Alert is ALFA Finder's top-priority alert: filings that can move a stock, such as orders, fund raises and approvals, sent to subscribers on Telegram within seconds of reaching the exchange.

Canara Bank Regulatory Approval

Canara Bank received RBI permission to exercise the call option on its Basel III AT1 bonds (ISIN INE476A08134) of Rs.1,500 Crore. The bank is now in process of exercising the call as per the issue terms.

Value

₹1,500 Cr

Regulatory ApprovalAlembic Pharmaceuticals Ltd APLLTDAlfa AlertAn Alfa Alert is ALFA Finder's top-priority alert: filings that can move a stock, such as orders, fund raises and approvals, sent to subscribers on Telegram within seconds of reaching the exchange.

Alembic Pharmaceuticals Regulatory Approval

Alembic Pharmaceuticals received USFDA final approval for Valganciclovir for Oral Solution, 50 mg/mL. This adds to its cumulative 247 USFDA ANDA approvals.